Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2

Status

Completed 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Melanoma 2

Interventions

Cyclophosphamide 109Radiotherapy 106Fluorouracil 76Doxorubicin 74Carboplatin 71Etoposide 67Cisplatin 67Vincristine 66Paclitaxel 58Chemotherapy, Adjuvant 53Leucovorin 47Specimen Handling 43Cytarabine 42Magnetic Resonance Spectroscopy 38Methotrexate 37Dexamethasone 33Taxes 31Bevacizumab 31Peripheral Blood Stem Cell Transplantation 30Gemcitabine 30Filgrastim 30Docetaxel 30Tamoxifen 28Melphalan 28Immunoglobulin G 25Epirubicin 25Disulfides 25Oxaliplatin 24Daunorubicin 24Prednisone 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × NIH × Tumor Necrosis Factor-alpha × Clear all
NCT00003789 2013-07-16

Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Locally Advanced Melanoma of the Arm or Leg

National Cancer Institute (NCI)

Phase 3 Completed
216 enrolled
Dermatologic

Melanoma

NCT00001296 2008-03-04

A Randomized Phase III Trial of Hyperthermic Isolated Limb Perfusion With Melphalan, Tumor Necrosis Factor, and Interferon-Gamma in Patients With Locally Advanced Extremity Melanoma

National Institutes of Health Clinical Center (CC)

Phase 3 Completed
122 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡